Welcome to our dedicated page for Diamedica Therapeutics SEC filings (Ticker: DMAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DiaMedica Therapeutics Inc. (DMAC) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke, DiaMedica uses SEC filings to report material clinical, regulatory, financing and governance events.
Recent Form 8-K filings illustrate how these documents inform investors about key developments. For example, DiaMedica has filed 8-Ks describing an in-person pre-IND meeting with the U.S. Food and Drug Administration for its planned U.S. Phase 2 preeclampsia study, including the FDA’s request for an additional non-clinical embryo-fetal development and pre- and postnatal development study in a rabbit model. Other 8-Ks detail private placement transactions, a Sales Agreement for an at-the-market equity offering program, and the entry into related securities purchase and registration rights agreements.
DiaMedica also uses 8-K filings to furnish quarterly financial results press releases, outline changes in executive leadership such as the appointment of a new Chief Medical Officer, and summarize separation agreements with departing officers. These filings complement the company’s periodic reports, which contain broader discussions of risk factors, clinical trial status, cash resources and operating expenses.
On Stock Titan, users can access DiaMedica’s 10-K annual reports, 10-Q quarterly reports, 8-K current reports and related exhibits as they are posted to EDGAR. AI-generated summaries highlight important sections, such as clinical development updates, capital-raising arrangements, and key contract terms, helping readers quickly understand what each filing means for DM199 and the company’s broader pipeline. Form 4 insider transaction reports, when available, can also be reviewed to see how officers and directors are transacting in DMAC shares.
DiaMedica Therapeutics Inc. (DMAC) – Form 4 insider transaction: On 07/23/2025, 10% owner and director Jan Stahlberg, through his wholly-owned entity Trill AB, purchased 1,542,857 common shares of DMAC at $3.50 per share (Code “P”).
Following the buy, Stahlberg’s indirect holding via Trill AB rose to 6,764,465 shares. No derivative securities were reported. The filing signals a sizeable capital outlay of roughly $5.4 million, lifting the insider’s stake and reinforcing alignment with public shareholders.